Analyst Price Target is $12.00
▼ -23.13% Downside Potential
This price target is based on 7 analysts offering 12 month price targets for NeuroPace in the last 3 months. The average price target is $12.00, with a high forecast of $22.00 and a low forecast of $9.00. The average price target represents a -23.13% upside from the last price of $15.61.
Current Consensus is
The current consensus among 7 contributing investment analysts is to moderate buy stock in NeuroPace. This Moderate Buy consensus rating has held steady for over two years.
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. The company's RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip leads and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.